SynthesisImmunologic research2025
Maternal RSV vaccine: a systematic review and meta-analysis of immunogenicity and perinatal safety.
Synthesis in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of maternal RSV vaccination against infant lower respiratory tract infections: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Review
- Introducing the Concept of Small Vulnerable Newborns (SVN) as an Additional Endpoint to Evaluate Birth Outcomes in the Context of RSV Immunization Studies-A Commentary.Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis assess the immunogenicity and maternal-fetal safety profile of RSV prefusion F (RSVpreF) vaccination during pregnancy. PubMed, Scopus, Embase, Cochrane, and Web of Science databases were searched for relevant studies. Only randomized controlled trials (RCTs) evaluating the safety, efficacy, and immunogenicity of RSVpreF vaccination in pregnant women were included. Six RCTs, involving 17,212 participants, were analyzed. The vaccine significantly boosted maternal anti-RSV neutralizing antibody levels, with a standardized mean difference (SMD) of 1.40 for RSV-A and 1.11 for RSV-B, both with high statistical significance. Infants born to vaccinated mothers had a 49% reduced risk of RSV-associated lower respiratory tract illness within 180 days post-vaccination (OR = 0.51, 95% CI: 0.40-0.64). Preterm birth rates did not differ significantly between the vaccine and placebo groups (OR = 1.09, 95% CI: 0.87-1.37). The vaccine was not associated with increased risks of serious adverse events or perinatal complications. Maternal RSVpreF vaccination significantly elevates neutralizing antibody levels against RSV subtypes A and B without increasing the risk of serious adverse events or preterm delivery. These findings support the safety and immunogenicity of RSV vaccination in pregnant women, reinforcing its potential utility in protecting neonates against RSV-related morbidity.
Indexed as
Identifiers
41455011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.